UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000036526
Receipt number R000041230
Scientific Title Effects of the enternal administration of Bifidobacterium breve (BBG-01, Yakult) for dysbiosis of infants born by C-section on of their growth and development
Date of disclosure of the study information 2019/04/16
Last modified on 2022/04/18 13:12:52

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Effects of the enternal administration of Bifidobacterium breve (BBG-01, Yakult) for dysbiosis of infants born by C-section on of their growth and development

Acronym

Probiotics supplementation for improvement of intestinal bacteria in infants born by C-section

Scientific Title

Effects of the enternal administration of Bifidobacterium breve (BBG-01, Yakult) for dysbiosis of infants born by C-section on of their growth and development

Scientific Title:Acronym

Probiotics for C-section born infants

Region

Japan


Condition

Condition

Infants born by C-section

Classification by specialty

Pediatrics

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

To confirm that improvement of dysbiosis and benefits to growth of the subjects with daily supplement of bifidobacteria in the early infant days

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Improvement of dysbiosis, including early colonization and its persistence of bifidobacteria

Key secondary outcomes

1. Infant growth and development, 2. Intestinal microbiota, 3. Intestinal environment


Base

Study type

Interventional


Study design

Basic design

Parallel

Randomization

Randomized

Randomization unit

Individual

Blinding

Double blind -all involved are blinded

Control

Placebo

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

2

Purpose of intervention

Prevention

Type of intervention

Food

Interventions/Control_1

Daily supplement of bifidobacterial from the 1st day of life for one month

Interventions/Control_2

Daily supplement of placebo from the 1st day of life for one month

Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit

1 days-old <=

Age-upper limit

1 days-old >=

Gender

Male and Female

Key inclusion criteria

Apparently healthy newborns by C-section

Key exclusion criteria

Newborn those who are judged in appropriate for the enrollment for the study by one of doctors who performed C-section, charged for the study or the final responsibility

Target sample size

50


Research contact person

Name of lead principal investigator

1st name Yuichiro
Middle name
Last name Yamashiro

Organization

Juntendo University Graduate School of Medicine

Division name

Probiotics Research Laboratory

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-5689-0082

Email

yamasiro@juntendo.ac.jp


Public contact

Name of contact person

1st name Yuichiro
Middle name
Last name Yamashiro

Organization

Juntendo University Graduate School of Medicine

Division name

Probiotics Research Laboratory

Zip code

113-8421

Address

2-1-1 Hongo, Bunkyo-ku, Tokyo

TEL

03-5689-0082

Homepage URL


Email

yamasiro@juntendo.ac.jp


Sponsor or person

Institute

Juntendo University

Institute

Department

Personal name



Funding Source

Organization

Juntendo University

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization

Japan


Other related organizations

Co-sponsor

Yakult Central Institute

Name of secondary funder(s)



IRB Contact (For public release)

Organization

Juntendo Hospital Ethics Committee

Address

3-1-3 Hongo, Bukyo-ku, Tokyo

Tel

03-5802-1584

Email

kenkyu5858@juntendo.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

順天堂大学医学部附属順天堂医院(東京都)


Other administrative information

Date of disclosure of the study information

2019 Year 04 Month 16 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

No longer recruiting

Date of protocol fixation

2019 Year 04 Month 03 Day

Date of IRB

2019 Year 04 Month 03 Day

Anticipated trial start date

2019 Year 05 Month 21 Day

Last follow-up date

2022 Year 12 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 04 Month 16 Day

Last modified on

2022 Year 04 Month 18 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000041230


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name